Den europeiske union -
kroatisk -
EMA (European Medicines Agency)
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubicin hidroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
Kroatia -
kroatisk -
Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane
novacoc forte
richter pharma ag, feldgasse 19, 4600 wels, austrija - metamizolnatrij; kofein; kalcijev glukonat za injekciju; magnezijev glukonat; natrijev dihidrogenfosfat dihidrat; acetilmetionin; glukoza hidrat - otopina za infuziju - analgetici - konja, goveda i svinja
Kroatia -
kroatisk -
Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane
novacoc forte
vetviva richter gmbh, durisolstrasse 14, 4600 wels, austrija - metamizolnatrij; kofein; kalcijev glukonat za injekciju; magnezijev glukonat; natrijev dihidrogenfosfat dihidrat; acetilmetionin; glukoza hidrat - otopina za infuziju - konja, goveda i svinja
Den europeiske union -
kroatisk -
EMA (European Medicines Agency)
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
Kroatia -
kroatisk -
Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane
calcibel
bela-pharm gmbh & co. kg, lohner straße 19, 49377 vechta, njemačka - kalcijev glukonat ; magnezijev klorid heksahidrat ; boratna kiselina - otopina za infuziju - otopina za infuziju koja sadržava kalcij i magnezij; kalcij, u kombinaciji s drugim farmaceutskim proizvodima - konja, goveda, ovaca, koza, svinja